Jul 14, 2026·Score 75·Type A — Value-style analysisUsed for established, cash-generative companies — weighs earnings power, valuation against the company's own history and peers, and margin of safety.Full methodology →
Current PriceThe market price around the time this report was written — not a live quote. The market has moved since; check a current price before acting.Methodology →$303.44
Buy ZoneThe large figure is the midpoint of the suggested buy range shown in parentheses.$275.00($265.00–$285.00)
Target PriceOur estimated fair value. For richly valued stocks it can sit below the current price — see Methodology.Methodology →$353.50
Expected Return
Target relative to the Current Price ((Target − Current) ÷ Current). Since that price is from the report date, your actual return will differ.
A negative figure isn't an error. For richly valued stocks, the fair-value target can sit below the current price, so the return reads negative. The grade reflects company quality; this figure reflects today's entry valuation.
Type A - Cencora, Inc. (COR) 20260714 Stock Analysis
📅 Cencora Key Upcoming Events
August 05, 2026Q3 Fiscal 2026 Earnings Release and Conference Call
Description: Cencora is scheduled to release its fiscal third-quarter results prior to the market open, followed by a live conference call. This event is a critical juncture for the company to demonstrate whether the transitory headwinds from manufacturer list price reductions observed in Q2 have subsided, and to provide updates on the financial synergies emerging from the newly integrated OneOncology platform.
August 14, 2026Projected Ex-Dividend Date for Fiscal Q4 Dividend
Description: Based on historical payout schedules and dividend declaration patterns, Cencora is expected to go ex-dividend for its next quarterly payout of $0.60 per share in mid-August. This upcoming distribution reinforces the company’s elite 22-year streak of consecutive dividend growth and reflects its robust free cash flow generation.
September 30, 2026End of Fiscal Year 2026
Description: This date marks the close of a highly transformational fiscal year for the organization. It caps a period defined by massive capital reallocation, specifically the multi-billion dollar divestiture of MWI Animal Health and the aggressive, debt-funded acquisitions of leading human specialty management service organizations (MSOs) like Retina Consultants of America and OneOncology.
🏢 Step 1: Cencora Company Overview & Business Model
Q1-A1. What is Cencora?
Company Name (Ticker): Cencora, Inc. (COR)
Sector: Healthcare
Exchange: NYSE
Founded: August 29, 2001
Listing Date: April 04, 1995
Fiscal Year End: September
Headquarters: United States, Conshohocken
CEO: Robert P. Mauch
Market Cap: $59.04B
Shares Outstanding: 194.56M
Current Stock Price: $303.44
Annual Dividend Yield:0.79%
Ex-dividend Date: May 15, 2026 (ET, historical basis)
As-of: July 14, 2026 (ET)
Q1-A2. How Does Cencora Make Money?
Core Pharmaceutical Distribution Engine: Cencora (formerly AmerisourceBergen) functions as a foundational, indispensable pillar of the global healthcare supply chain. The company purchases pharmaceuticals in massive quantities from drug manufacturers and efficiently distributes them to a sprawling network of retail chain pharmacies, independent pharmacies, mail-order facilities, hospital networks, and other healthcare providers. Cencora generates its primary revenue by capturing a distribution spread—a fee or percentage based on the wholesale acquisition cost (WAC)—between the acquisition of medications and their final delivery to dispensaries.
Specialty Solutions and MSO Platforms: Recognizing the razor-thin margins of traditional generic and branded pill distribution, Cencora has aggressively evolved into high-margin specialty drug logistics and Management Services Organizations (MSOs). Through monumental acquisitions such as Retina Consultants of America (RCA) and OneOncology, Cencora now empowers independent medical specialty practices by providing comprehensive administrative, clinical, and operational support. This pivot allows the company to capture a far greater, highly profitable share of the healthcare value chain, directly assisting physicians with complex cancer and ophthalmic treatments.
Commercialization and Global Logistics: Through its specialized World Courier division, Cencora provides ultra-secure, temperature-controlled logistics for highly complex biopharmaceuticals, gene therapies, and clinical trials on a global scale. This niche requires immense technological capability and stringent regulatory compliance, allowing the company to earn premium fees for mission-critical transportation services that ordinary logistics providers cannot execute.
Q1-A3. Cencora’s Revenue Segments & Core Income Sources
U.S. Healthcare Solutions (90.55% of Revenue): This is the undisputed dominant engine of Cencora’s enterprise, generating a staggering $290.98 billion in fiscal 2025 alone. It encompasses the distribution of brand-name, generic, and specialty pharmaceuticals strictly to United States-based providers. Recently, this segment’s growth has been structurally supercharged by the explosion in GLP-1 weight-loss and diabetes drug volumes. Furthermore, the integration of highly profitable MSO networks like OneOncology directly filters into this segment, acting as a crucial margin-enhancement lever against the commoditization of traditional drug distribution.
International Healthcare Solutions (9.45% of Revenue): Generating roughly $30.37 billion in fiscal 2025, this segment includes Alliance Healthcare (one of the premier drug wholesalers operating across Europe) alongside the World Courier business. While it represents a smaller portion of total revenue, it provides indispensable geographic diversification and contributes high-margin global logistics capabilities that insulate the overall business from singular U.S. regulatory or pricing shocks.
Q1-A4. Who Are Cencora’s Competitors?
Direct Oligopolistic Competitors: Cencora operates within a highly consolidated, impenetrable U.S. pharmaceutical wholesale oligopoly alongside McKesson Corporation (MCK) and Cardinal Health, Inc. (CAH). Together, these three behemoths command over 90% of the domestic market share. McKesson is slightly larger by both market capitalization and total revenue volume, while Cardinal Health maintains a highly competitive stance in medical-surgical supply distribution.
Industry Position Assessment: Cencora differentiates itself from McKesson and Cardinal Health through a deliberate, heavier strategic weighting toward specialty pharmaceuticals, oncology, and independent physician practice management. The strategic divestiture of its animal health unit (MWI) and its heavy, debt-funded investments into OneOncology and RCA demonstrate a clear, calculated pivot toward dominating complex, human specialty care, giving Cencora a distinct competitive advantage in the fastest-growing therapeutic areas.
Q1-A5. Cencora Key Events: Past 12 Months
September 30, 2025Recording of $723.9 million goodwill impairment charge
Description: During its fiscal Q4 2025, Cencora recorded a substantial non-cash goodwill impairment charge related to its PharmaLex acquisition, heavily impacting GAAP net income but appropriately excluded from the company’s adjusted operating metrics, reflecting a valuation reset for specific consulting assets.
February 02, 2026Cencora completes $4.6 billion acquisition of OneOncology
Description: In a massive strategic maneuver, Cencora acquired the remaining majority equity interest in OneOncology. Funded entirely via new debt financing, this brought a structurally vital oncology management platform fully into its U.S. Healthcare Solutions segment to drive long-term operating margin expansion.
February 18, 2026Divestiture of MWI Animal Health in a $3.5 billion merger with Covetrus
Description: Cencora agreed to merge its animal health segment with privately held Covetrus. Cencora received $1.25 billion in cash and maintained a minority stake in the combined entity, effectively shedding non-core assets to focus its capital entirely on human specialty pharmacy.
March 23, 2026Cencora acquires EyeSouth Partners’ retina business for $1.1 billion
Description: Continuing its aggressive MSO rollup strategy, Cencora purchased EyeSouth’s retina business, seamlessly folding these highly specialized physicians into its existing Retina Consultants of America (RCA) network to cement its dominance in ophthalmic specialty care.
May 06, 2026Fiscal Q2 2026 earnings reveal a massive revenue miss due to list price cuts
Description: The stock plunged over 17% in a single trading session after Cencora reported $78.4 billion in revenue against an $81.09 billion consensus. The top line was battered by manufacturer list price reductions and the loss of two large customers, despite management successfully raising full-year EPS guidance.
May 21, 2026Authorization of a new $2.0 billion share repurchase program
Description: Capitalizing swiftly on the post-earnings stock collapse, the Board of Directors authorized a massive $2.0 billion stock buyback program, signaling immense internal confidence in the company’s free cash flow generation and underlying margin health.
June 29, 2026Eva C. Boratto officially assumes the role of Chief Financial Officer
Description: Bringing deep healthcare and pharmacy benefit management (PBM) experience from a prior tenure as CFO of CVS Health, Boratto succeeds the retiring James F. Cleary, tasked with navigating Cencora’s elevated debt load and optimizing MSO integration.
Q1-A6. Step 1 Key Takeaways
Step 1 Summary: Cencora is currently executing a profound structural transformation, trading top-line animal health and consulting revenues for higher-margin, stickier specialty physician platforms (OneOncology, RCA), all while maintaining its untouchable moat in the U.S. pharmaceutical distribution oligopoly.
Top 3 Red Flags:
1 Significant $2 billion revenue headwind explicitly generated by manufacturer list price reductions, severely impacting top-line visibility and causing the Q2 2026 earnings shock.
2 Elevated debt levels, reaching $12.39 billion in total debt, stemming directly from the OneOncology and RCA acquisitions, which has pushed net interest expenses to an estimated $485 million annually.
3 Structural customer attrition, specifically the loss of a major oncology customer and a grocery retail customer, which measurably dragged down Q2 2026 volume growth.
Top 5 Key Financial/Operational Indicators for Next-Level Analysis:
1 Operating Margin Expansion trajectory (tracking the successful integration of high-margin MSOs).
2 Adjusted Free Cash Flow realization against the firm’s $3.0 billion target for FY26.
3 Net Interest Expense trajectory and the speed of post-acquisition deleveraging.
4 GLP-1 medication revenue growth compared to its actual margin contribution.
5 Return on Invested Capital (ROIC) stability amid aggressive M&A capital deployment.
Top 3 Unconfirmed and Estimated:
1 Exact timeline and execution capability for deleveraging back to historical 1.5x debt-to-EBITDA levels.
2 The ultimate, long-term margin impact of rapid brand-to-biosimilar conversions at large mail-order pharmacies.
3 Potential FTC or regulatory scrutiny over massive MSO roll-ups in community oncology and retina specialties.
🏰 Step 2: Cencora’s Economic Moat, Growth & Capital Allocation
Q2-A1. Does Cencora Have a Durable Economic Moat?
Entry barriers: Cencora benefits from exceptionally wide and robust economic moats built upon insurmountable scale, complex regulatory compliance infrastructure, and razor-thin distribution margins that structurally repel new market entrants. Operating a highly synchronized, national logistics network capable of cold-chain biological transport requires decades of capital investment and stringent DEA/FDA compliance mechanisms that cannot be replicated easily or cheaply by startups.
Pricing power: As a wholesale distributor, traditional pricing power is inherently limited by the transparency of manufacturer wholesale acquisition costs (WAC); however, Cencora commands tremendous purchasing power. By pooling national demand, it negotiates highly favorable terms with both generic and branded manufacturers. Furthermore, in its specialty MSO businesses (RCA, OneOncology), Cencora exercises stronger pricing power by optimizing practice management workflows and driving lucrative clinical trial participation.
Profitability defense: The entrenched oligopoly structure guarantees that Cencora, McKesson, and Cardinal Health act rationally rather than engaging in mutually destructive price wars. Exceptionally high switching costs exist for hospitals and pharmacies that are deeply integrated into Cencora’s IT and inventory management systems (such as the proprietary Nucleus solution), virtually guaranteeing long-term customer retention and sustained Return on Invested Capital (ROIC) substantially above the industry’s cost of capital.
Q2-A2. Is Cencora’s Growth Sustainable?
Industry Structure and Growth Outlook: The United States pharmaceutical market is undergoing structural expansion, driven relentlessly by an aging demographic, the increased prevalence of chronic diseases, and an explosion in costly specialty biologics and GLP-1 weight-loss agonists. Cencora is perfectly positioned to capture roughly one-third of this continuously expanding Total Addressable Market (TAM).
Growth Sustainability: The company’s growth profile is highly sustainable and structural rather than purely event-driven. The deliberate strategic pivot toward specialty care and physician MSOs effectively insulates the company from the deflationary commoditization of standard generic pills.
Downside Scenarios:
1 Aggressive government intervention, such as sweeping Pharmacy Benefit Manager (PBM) reform or heavy-handed Medicare negotiations, that artificially suppresses branded drug list prices, thereby crushing percentage-based distribution spreads.
2 Faster-than-expected margin compression from aggressive biosimilar substitution if Cencora fails to technologically or contractually capture the economics of the switch at the pharmacy level.
3 Over-leveraging the balance sheet through continued rapid-fire M&A, leading to a credit downgrade and strangling free cash flow via spiraling interest costs in a “higher for longer” macroeconomic rate environment.
Q2-A3. How Does Cencora Allocate Capital & Return Cash?
Capital Allocation Strategy: Executive management demonstrates aggressive, highly targeted capital deployment capabilities. Over the past 24 months, Cencora systematically allocated over $10 billion to acquire the OneOncology platform, Retina Consultants of America, and EyeSouth’s retina business. Concurrently, they executed a successful divestiture of the non-core MWI Animal Health division for $3.5 billion, representing a masterful display of portfolio optimization toward human specialty care.
Shareholder Returns: Despite enduring a heavy M&A cycle, the company consistently generates approximately $3.0 billion in annual free cash flow. While Cencora paused buybacks briefly in early 2026 to digest the OneOncology deal, it swiftly authorized a massive $2.0 billion share repurchase program in May 2026 to aggressively capitalize on a post-earnings stock dip. Furthermore, the dividend has been raised for 22 consecutive years, highlighting an unwavering commitment to returning cash to shareholders.
Economic Moat (9/10): Cencora possesses an almost impenetrable oligopolistic position with extreme scale advantages and sticky healthcare IT integration that makes customer churn rare.
Growth Sustainability (7/8): Unstoppable structural demographic tailwinds and a brilliant, timely pivot to specialty oncology and retina care ensure durable, long-term growth.
Capital Allocation (6/7): Management executes excellent strategic M&A and highly profitable divestitures, coupled with robust buybacks, though temporary debt accumulation from the OneOncology deal poses mild friction.
Step 2 Summary: Cencora’s structural dominance in drug distribution is effectively unassailable, and management’s aggressive capital recycling out of animal health and into high-margin specialty MSOs ensures the company remains at the absolute apex of healthcare profit pools.
💰 Step 3: Is Cencora Profitable? Financial Health Analysis
Q3-A1. Cencora’s Growth & Profitability Trends
Analysis of Growth and Revenue Indicators: Cencora delivered $321.3 billion in revenue in FY25 (a robust 9.3% YoY increase). However, Q2 FY26 revenue of $78.4 billion represented a noticeable deceleration to 3.8% YoY growth, severely missing Wall Street consensus estimates due to a heavy $2 billion structural headwind from manufacturer list price cuts and discrete, previously announced customer attrition. Despite this top-line shock, adjusted operating income grew by an impressive 6% in Q2 FY26, showcasing the absolute resilience of the underlying profit engine.
Profitability Margin and Leverage Verification: Operating margins in the drug distribution space are structurally microscopic, yet Cencora’s adjusted gross profit as a percentage of revenue expanded by 45 basis points to 4.31% in Q2 2026. Consequently, the operating margin climbed to 1.46% on a GAAP basis (up from 1.37% the prior year). This slight but critical margin expansion provides empirical proof that the strategic addition of OneOncology and RCA is successfully driving real ‘operating leverage’—allowing profits to grow faster than top-line revenue.
Q3-A2. How Profitable Is Cencora? (Margins & ROIC)
ROIC and Value Creation: Cencora operates as an extraordinarily capital-efficient machine. Return on Invested Capital (ROIC) stands at an exceptional 21.4% on a trailing twelve-month basis. This vastly exceeds the company’s estimated Weighted Average Cost of Capital (WACC) of roughly 7.1%, indicating massive and continuous economic value creation for shareholders.
Industry Comparison: Cencora’s ≈21% ROIC is fundamentally superior to McKesson’s ≈16% ROIC, highlighting Cencora’s superior operational execution and highly accretive specialty M&A strategy that extracts more profit per dollar of deployed capital than its largest rival.
Q3-A3. What Drives Cencora’s Returns? (ROIC Breakdown)
Key Driver (Distribution/Platform Efficiency): As a high-volume distributor and MSO operator, operational efficiency is driven entirely by massive inventory turnover combined with meticulous gross margin optimization.
Analysis: Cencora’s gross margin expansion to 4.31% in Q2 2026 was directly propelled by the integration of the high-margin OneOncology platform. By efficiently turning over hundreds of billions of dollars in low-margin generic and brand inventory while simultaneously layering on highly lucrative specialty MSO administrative fees, Cencora maximizes absolute profit generation against a relatively light physical asset base.
Q3-A4. Are Cencora’s Earnings High Quality?
Profit to Cash Conversion: Cencora exhibits superb earnings quality. Net income is routinely backed by robust, tangible operating cash flow. The company confidently expects to generate $3.0 billion in adjusted free cash flow in FY26, matching its impressive FY25 performance.
Trend: The Cash Conversion Rate (FCF/NI) has historically hovered at or above 1.0x, indicating that the GAAP earnings reported by Cencora are fully backed by actual cash entering the business, completely devoid of aggressive accounting fictions or uncollected receivables.
Q3-A5. Is Cencora’s Balance Sheet Healthy? (Debt & Leverage)
Debt Structure: Total debt spiked to $12.39 billion by March 2026, up significantly from $7.66 billion at the end of FY25, a surge directly driven by the $5.5 billion in term loans and credit facilities tapped to acquire OneOncology.
Leverage and Refinancing: This debt accumulation pushed EBITDA leverage from 1.3x at FY24 to an estimated 2.5x in FY26. While this represents an elevated level of leverage, Fitch Ratings recently affirmed Cencora’s ‘A-’ credit rating, citing strong confidence that the company will deploy its $3 billion annual FCF to aggressively pay down $3.9 billion in debt by FY28, ensuring total solvency.
Interest Repayment: Interest expense has surged to a projected $485 million for FY26 (up sharply from $292 million in FY25) due to the higher rate environment on new acquisition debt. Nonetheless, with over $5.3 billion in TTM EBITDA, the interest coverage ratio remains robust at approximately 10x, presenting absolutely no immediate bankruptcy or liquidity risk.
Profitability·Capital Efficiency (8/10): Exceptional 21% ROIC easily beats immediate peers, with gross margins visibly expanding due to highly successful specialty M&A.
Cash Flow·Profit Quality (7/8): Ironclad cash conversion metrics, reaffirming a massive, highly predictable $3.0 billion FCF target for FY26.
Financial Soundness·Debt Management (6/7): The temporary leverage spike to 2.5x EBITDA creates a noticeable interest rate drag on net income, but solvency remains highly secure under a rock-solid A- credit rating.
Step 3 Summary: Cencora is an exceptional, durable cash-generating engine that is currently digesting a heavy, debt-funded M&A cycle; strong underlying cash flows guarantee rapid future deleveraging.
Evidence: Revenue is recognized straightforwardly upon delivery of pharmaceutical products or the provision of MSO services; no aggressive pull-forward mechanisms or channel stuffing were detected in the SEC filings.
Cost capitalization: not found
Evidence: Standard distribution capex and software investments are capitalized normally in accordance with strict GAAP standards.
Sharp increase in accounts receivable and inventory: not found
Evidence: Receivables and inventory scale linearly and proportionally with the massive $328 billion TTM revenue base; days sales outstanding (DSO) and inventory turnover ratios remain highly stable and predictable.
Evidence: The Q2 2026 GAAP net income of $1.64 billion included a massive $1.1 billion non-cash remeasurement gain related to the previously held equity investment in OneOncology. Management properly and transparently stripped this out to report $4.75 in adjusted EPS, avoiding any distortion of operational reality. Furthermore, in Q4 2025, a $723.9 million goodwill impairment charge regarding PharmaLex was appropriately adjusted out.
Q4-A2. Is Cencora Overspending? (Capex & Capital Cycle)
➖ Not applicable: As a wholesale distributor and healthcare services provider, Cencora does not manufacture physical goods that are subject to factory oversupply or cyclical commodity gluts. Capex is strictly guided at a modest $900 million for FY26 (focused primarily on IT integration and warehouse optimization), which is entirely appropriate and highly restrained for a $330 billion revenue company.
Q4-A3. How Sound Is Cencora’s Cash Flow?
Quality of Profits: Operating Cash Flow consistently matches or exceeds stated net income.
Stability: The company is entirely self-funding for its day-to-day operational needs. It utilizes external debt strictly for massive strategic acquisitions (like OneOncology and RCA) rather than bridging any operational cash burn.
Confirmed (Past) Dilution: The total number of outstanding shares has steadily declined over the past five years, dropping from roughly 209 million in 2021 to 194.56 million today, demonstrating a structural commitment to net anti-dilution.
Potential (Future) Dilution & Overhang: In May 2026, the Board of Directors authorized a massive new $2.0 billion share repurchase program. This aggressive buyback initiative completely absorbs and mitigates any standard Stock-Based Compensation (SBC) dilution, ensuring strong EPS accretion for existing shareholders.
Q4-A5. Data Integrity Check
Period: FY vs TTM/Quarterly Standardization (TTM ending March 31, 2026) ➡ (Pass)
Definition: GAAP vs Non-GAAP EPS properly reconciled across all platforms (GAAP Q2 EPS $8.40 vs Adj EPS $4.75) ➡ (Pass)
Number of shares: Unified at 194.56 million diluted shares ➡ (Pass)
Unit: USD, Billions/Millions standard applied ➡ (Pass)
Accounting anomalies/distortion signals (8/8): Highly transparent financial reporting with clear, appropriate, and conservative non-GAAP adjustments utilized to account for massive M&A accounting noise.
Cash flow warning signals (7/7): Rock-solid cash conversion entirely immune from operational burn or liquidity crises.
Dilution factors (5/5): The company remains a consistent net-buyer of its own stock, a trend significantly bolstered by the fresh $2.0 billion buyback war chest authorized in May.
Step 4 Summary: Cencora’s financial statements are forensically clean, and management’s unwavering commitment to share cancellation provides a continuous, powerful tailwind to EPS.
Q5-A1. Can You Trust Cencora’s Management? (Guidance Track Record)
Guidance Hit Rate: CEO Bob Mauch and the broader executive team possess a stellar reputation for conservative guidance forecasting and consistent execution. However, in May 2026, management faced a severe test when forced to abruptly cut full-year consolidated revenue guidance from 7%-9% growth down to 4%-6% due to unexpected manufacturer list price reductions.
Transparency and Consistency: Crucially, while revenue guidance was slashed, management aggressively raised the Adjusted Operating Income growth guidance to 12%-14% and raised the EPS guidance floor to $17.65. This proves extreme transparency and operational control: they openly admitted top-line weakness but demonstrated absolute command over the bottom line through cost controls and MSO synergy realization.
Q5-A2. What Are Cencora Insiders Doing?
Insider Trading Status: Insider buying behavior has signaled immense conviction following the brutal May earnings selloff. On May 28, 2026, and June 22, 2026, Independent Chairman of the Board Mark M. Durcan executed two massive open-market purchases of 4,000 shares each (totaling over $2.1 million) at prices between $266 and $274.
Executive Confidence: Conversely, CEO Robert Mauch executed routine, scheduled sells of roughly $4.7 million in January and February 2026 at high prices near $355-$359. However, the aggressive cluster buying by the Chairman directly at the recent cyclical bottom serves as a textbook, high-conviction psychological signal that the Board believes the market severely overreacted.
Q5-A3. Is Cencora’s Management Aligned With Shareholders?
Voting Rights and Governance Check: Cencora operates with a standard, highly shareholder-friendly single-class voting structure with no differential voting rights.
Performance and Compensation Indicators: Walgreens Boots Alliance remains a major stakeholder (owning roughly 10% of the equity), ensuring that executive compensation metrics are tightly bound to strict ROIC targets, adjusted EPS growth, and absolute total shareholder return.
Incentive Alignment: The seamless executive transition to Eva Boratto as the new CFO in June 2026, succeeding the retiring James Cleary, demonstrates deep corporate bench strength and institutional stability without disrupting shareholder alignment.
Management Trust (4/5): Highly credible bottom-line execution and transparency, though slightly dinged by the severity of the recent top-line revenue guidance shock.
Insider Trends (4/5): A tremendous bullish signal generated by the Chairman’s $2M+ cluster buy at the $266 support level, which easily offsets the routine, algorithmic CEO selling from earlier in the year.
Governance & Compensation System (4/5): Clean, transparent corporate structure with major institutional oversight from Walgreens ensuring strong incentive alignment.
Step 5 Summary: Cencora’s leadership is battle-tested, highly financially disciplined, and backed by independent board members willing to deploy substantial personal capital during extreme market dislocations.
⛵ Step 6: Cencora Market Flow & Sentiment
Q6-A1. Analyst Consensus vs Cencora Guidance
Guidance Gap and Direction Analysis: Cencora’s revised FY26 EPS guidance range of $17.65 to $17.90 sits perfectly in line with Wall Street’s $17.78 median consensus. Market expectations for total revenue were definitively broken in Q2 2026, causing a massive sentiment reset, though bottom-line EPS expectations remain completely intact and highly achievable.
Tracking Recent Sentiment Changes: Analysts from institutions like Wells Fargo and Barclays immediately downgraded their price targets (e.g., Wells Fargo slashing the target from $429 to $331) following the Q2 revenue miss, citing a slower U.S. sales outlook and GLP-1 margin concerns. Market sentiment shifted violently from euphoric in early 2026 to highly cautious by mid-summer.
Q6-A2. What Is Cencora’s Short Interest?
Institutional Trends: Institutional ownership remains exceptionally high, hovering around 78% (with major anchor holders including BlackRock, Vanguard, and State Street), indicating deep structural support.
Short Selling Indicators: Short interest sits at an anemic 2.87% of the float (accounting for roughly 5.28 million shares), requiring approximately 4.09 Days-to-Cover. This data explicitly proves that hedge funds view Cencora as fundamentally robust and are completely unwilling to bet heavily against it, despite the recent top-line revenue miss.
Consensus vs Guidance (2/3): The severe Q2 top-line guidance miss damaged short-term momentum and triggered target cuts, though bottom-line consensus remains heavily supported by management’s track record.
Supply/Short Interest (2/2): Short sellers are virtually non-existent, reflecting ironclad institutional support and a massive defensive baseline.
Step 6 Summary: The stock is currently locked in the “penalty box” regarding top-line momentum, but zero predatory short-selling suggests the broader market views the $260-$290 level as a hard fundamental floor.
🚀 Step 7: Cencora Catalysts & Price Triggers
Q7-A1. What Could Move Cencora Stock? (Top 3 Catalysts)
1 Acceleration of OneOncology and RCA margin synergies
Timing: Next 6-12 months
Success Conditions: Management successfully scales the newly acquired MSO platforms without integration hiccups, driving adjusted operating margins definitively and consistently above the 1.5% barrier.
Failure Risk: Elevated variable financing costs outpace the margin accretion, resulting in stagnant or declining EPS growth.
2 Structural stabilization of U.S. GLP-1 and Specialty drug volumes
Timing: Next 6 months
Success Conditions: The massive, explosive demand for GLP-1 agonists stabilizes into predictable, profitable distribution channels, finally dispelling analyst fears of permanent margin dilution.
Failure Risk: Continued manufacturer list price cuts and an unfavorable low-margin GLP-1 mix drag down absolute gross profit dollars generated by the U.S. segment.
3 Aggressive execution of the $2.0 billion share repurchase program
Timing: Next 6-12 months
Success Conditions: Cencora aggressively and opportunistically retires shares near the $270-$300 support level, providing a massive mechanical boost to FY27 EPS metrics.
Failure Risk: Buybacks are severely delayed due to free cash flow being forcefully diverted to service the $12.4 billion debt load under pressure from credit rating agencies.
Q7-A2. Cencora’s Earnings Revision Trend
Tracking EPS Estimate Changes: Despite the violent stock price collapse in May 2026, analysts have largely maintained or slightly raised EPS estimates. Out of 11 recent major revisions tracked, an overwhelming 10 were upward adjustments for FY26 earnings.
Earnings Expectations and Momentum: The market has clearly bifurcated its view: top-line revenue estimates have been slashed, but bottom-line EPS estimates are steadily rising due to explicit MSO margin expansion and relentless share buybacks. This divergence serves as a key secondary indicator for future stock price recovery once the top-line narrative normalizes.
Catalyst (6/7): The completion of the $4.6B OneOncology integration and the authorization of a $2B buyback serve as massive, highly tangible levers to force EPS higher independent of broader macro conditions.
EPS Trend (2/3): Analyst revisions remain solidly positive on the bottom line, though top-line sluggishness caps absolute immediate momentum.
Step 7 Summary: The definitive path to stock price recovery is entirely within management’s direct control: flawless execution of the MSO playbook, rapid debt paydown, and mechanically shrinking the outstanding float.
⚖️ Step 8: Is Cencora Fairly Valued? Valuation Analysis
Scoring Rationale: The absolute valuation multiples present a perfectly mixed picture. While Price-to-Sales and EV/Sales look extraordinarily cheap (which is structurally typical for massive distributors with low margins), the crucial Forward PE of 17x and EV/EBITDA of 13.6x sit squarely in the fair valuation tier.
📌 (1) Axis Q8-A1 Score:0
Q8-A2. Cencora vs Peers: Valuation Comparison
Multiple selection based on peer comparison: Forward PER
Calculation of peer-to-peer deviation rate: +11.56%
Scoring Rationale: Cencora’s Forward PE of roughly 17.1x trades at a notable, explicit premium compared to McKesson’s Forward PE of 15.3x. This ≈11.6% premium firmly places the stock in the Overvalued tier (+10% to +30%) relative to its closest, most comparable direct peer.
📌 (2) Axis Q8-A2 Score:-2
Q8-A3. Is Cencora Cheap or Expensive vs Its History?
Comparison Indicators: Trailing PER
Scoring Rationale: Cencora’s current Trailing PE is 23.2x. Over the past 5 years, the Max PE achieved was 49.5x and the Min PE was 11.5x. The current position within this historical band evaluates to: (23.2 - 11.5) / (49.5 - 11.5) × 100% = 30.7%. Falling explicitly in the bottom 20-40% range, it registers mathematically as Undervalued relative to its own historical peaks.
📌 (3) Axis Q8-A3 Score:+2
Q8-A4. What Growth Is Priced Into Cencora? (Reverse DCF)
Implied Growth Rate:1.68%
1 Methodology: Standard Reverse DCF
2 Core assumptions: Current Price $303.44, FCF per share $15.42 (calculated as $3B FCF / 194.5M shares), WACC 7.11%, Terminal Growth 2.0%
Achievable Growth Rate:6.00%
Basis: Analyst consensus EPS growth estimates and company-issued long-term operating income guidance.
Scoring Rationale: The broader market is currently pricing in a remarkably pessimistic 1.68% perpetual growth rate. With management firmly guiding for structural mid-single-digit growth, the +4.32 percentage point gap indicates a strong margin of safety, registering as Undervalued (+2 to +5%p gap).
📌 (4) Axis Q8-A4 Score:+2
Q8-A4-1. What Growth Hurdle Does the Market Demand From Cencora? (Reverse DCF Alternative)
Scoring Rationale: ➖ (Not applicable as Q8-A4 was successfully calculated with available data).
(3) Axis Q8-A3 (Historical Band Position): Undervalued
(4) Axis Q8-A4 (Justification for Growth): Undervalued
The four indicators are entirely split (0, -2, +2, +2) across the valuation spectrum. Lacking a required 3/4 majority consensus, this results in an automatic directional mismatch penalty.
📌 (5) Axis Q8-A5 Score:-2
Q8-A6. Cencora’s Asset & Stake Valuation
Scoring Rationale: ➖ Not Applicable. Cencora is an operating distributor, not a holding company or an asset-heavy REIT.
📌 (6) Axis Q8-A6 Score:➖
Q8-A7. Final Valuation Adjustment
Scoring Rationale: There are no extraordinary, paradigm-shifting exceptions that justify deviating from the mechanical scoring metrics established above.
Commentary: The valuation math flawlessly neutralizes itself. Cencora is historically cheap on a reverse DCF and historical band basis, but commands a rigid, mathematically proven premium over its main peer McKesson. The stock is perfectly “Fairly Valued.”
Step 8 Summary: The current stock price perfectly reflects reality: investors are paying a mild premium for Cencora’s specialty M&A pivot, effectively balanced against the inherent, structural cheapness of the distribution sector.
💀 Step 9: What Are the Risks of Cencora? Fatal Risks & Pre-Mortem
Q9-A1. What Are the Biggest Risks to Cencora?
1 Sudden revenue destruction from manufacturer list price reductions:
Cause: Drug manufacturers enact sudden wholesale acquisition cost (WAC) cuts to aggressively comply with government pressure or Medicaid negotiations.
Impact: Financial (Top-line revenue implodes, directly evidenced by the severe $2 billion headwind absorbed in Q2 2026).
Mitigation/Monitoring Indicators: Monitor Q3/Q4 U.S. Healthcare Solutions revenue growth to precisely verify if the cuts fully cycle out of year-over-year comps.
Cause: Sourcing $5.5 billion in variable and fixed debt to acquire OneOncology in a restrictive “higher for longer” interest rate regime.
Impact: Financial (Interest expenses nearly doubling to an estimated $485 million annually).
Mitigation/Monitoring Indicators: Track quarterly net debt paydown pace; Fitch explicitly requires FCF/Debt to climb above 20% by FY27 to maintain the A- rating.
Cause: Faster-than-anticipated brand-to-biosimilar conversions at major mail-order clients, fundamentally altering the margin structure.
Impact: Financial (Margin compression if Cencora fails to capture the biosimilar spread efficiently).
Mitigation/Monitoring Indicators: Observe quarterly adjusted operating margins to verify if specialty/oncology growth is effectively offsetting mail-order leakage.
Q9-A2. How Sensitive Is Cencora to the Economy?
1 Interest Rates (⬇): Extremely sensitive over the immediate 24-month horizon. Surging borrowing costs on $12.39 billion in total debt directly impact net income margins and potentially delay massive share repurchases if cash must be diverted.
2 Healthcare Policy / Regulation (⬇): Highly sensitive. Aggressive federal action or legislation designed to crack down on Pharmacy Benefit Managers (PBMs) or mandate extreme drug price transparency threatens the structural distribution spread that Cencora relies upon.
Q9-A3. Cencora Pre-Mortem: What Could Go Wrong?
1 Disastrous MSO Integration: The highly touted $4.6 billion OneOncology acquisition fails to generate expected synergies, plunging the U.S. segment’s operating margin backward while elevated interest costs bleed the balance sheet dry.
Early Warning Signal: Operating margins in the U.S. Healthcare Solutions segment dip below 1.2% in two consecutive quarters.
2 Defection of Major Hospital Networks: A ferocious price war breaks out between McKesson and Cencora, resulting in a margin-destroying race-to-the-bottom to retain anchor hospital networks.
Early Warning Signal: Sudden, unexplained loss of a top-5 customer cited in an 8-K or 10-Q filing.
3 GLP-1 Margin Dilution Accelerates: Explosive GLP-1 obesity drugs cannibalize higher-margin therapies but provide almost zero gross profit to distributors, creating hollow “empty calorie” revenue growth.
Early Warning Signal: Segment revenue surges by 10%+ while absolute gross profit dollars flatline or decline.
Q9-A4. Risk Adjustment Score Calculation
📊 Risk Adjustment Score:-12 pts
Reason for Calculation: Cencora falls firmly and undeniably into the -11 to -20 deduction range. The risks are no longer theoretical “psychological concerns”—they have already been quantitatively recorded in the financial statements. The $2 billion manufacturer price cut and structural customer losses resulted directly in a brutal Q2 2026 revenue miss and slashed top-line guidance.
Step 9 Summary: The broader market’s brutal 17% haircut on earnings day was a highly rational response to tangible top-line damage, mathematically justifying a severe structural risk deduction.
Commentary: The solidly impressive 87-point fundamental baseline is significantly handicapped by the -12 point risk adjustment stemming directly from the brutal Q2 2026 revenue breakdown, perfectly anchoring the stock in fundamental “Hold” territory.
Q10-A2. Should You Buy Cencora? (Recommendation)
Recommendation:Hold
Commentary: The stock is currently caught in a violent fundamental tug-of-war. Phenomenal specialty M&A execution and deep undervaluation against cash flow are severely suppressed by transitory revenue headwinds and a highly elevated $12.39 billion debt load.
Q10-A3. Investment Thesis in One Line
Cencora pairs unassailable oligopolistic distribution scale and brilliant specialty MSO expansion (bull case) against the gravitational drag of rising interest costs and unpredictable manufacturer price cuts (bear case).
Q10-A4. Cencora’s Price Trend & Key Drivers
Stock Price Trends Over the Past 12 Months:sideways movement
February 02, 2026Completion of $4.6 Billion OneOncology Acquisition
Description: Securing the massive MSO asset electrified the market, pushing the stock toward its 52-week high of $377.54 as institutional investors cheered the aggressive pivot to high-margin specialty care. ➡ Stock Price Surge
May 06, 2026Q2 2026 Earnings Revenue Miss
Description: Missing consensus by $2.7 billion due to manufacturer price cuts and customer attrition instantly shattered the growth narrative, wiping out billions in market cap in a single trading session. ➡ Stock Price Plunge
May 21, 2026$2.0 Billion Share Repurchase Authorization
Description: Management forcefully intervened in the market rout by authorizing a massive buyback and raising the EPS outlook, successfully creating a hard support floor near $260. ➡ Stock Price Stabilization
Q10-A5. Action Plan
Current Price:$303.44
Buy Zone:$275.00 ($265.00–$285.00)
Commentary: By comprehensively considering the company’s traditional intrinsic value (safety margin) and current market momentum, it calculates a Actionable Buy Zone that minimizes opportunity costs.
(1) Calculation of Fundamental Value: From the perspective of securing the ‘Margin of Safety,’ we target the $265-$285 band. This perfectly aligns with the exact price range where the Independent Chairman of the Board aggressively bought shares with personal capital in May and June 2026, establishing a verified floor.
(2) Momentum Premium/Discount Application: Given the ongoing drag from interest expenses and the severe lack of top-line revenue momentum, no momentum premium is assigned. The entry must be strictly grounded in fundamental undervaluation.
(3) Conclusion: The $275.00 midpoint offers a fortress-like margin of safety, trading safely below the 200-day moving average while allowing investors to co-invest directly alongside insider conviction levels.
Target Price:$353.50
Expected Return:+16.5% (vs. current price)
📍 Select target stock price calculation criteria:
Forward PER — Cencora’s stable oligopoly structure and highly predictable cash flows make earnings multiples the most reliable proxy for intrinsic valuation.
🧮 Target Price Calculation Formula:
Per share indicator based (Forward PER, P/FCF, etc.): $19.81 × 17.84x = $353.50
Basis for applying the multiple: A 17.84x multiple represents a very slight, reasonable premium to current forward levels (17.07x). This premium is justified by the expectation that the OneOncology margin synergies will fully materialize by FY27, neutralizing the temporary debt burden. The $19.81 input reflects the median consensus EPS for FY27.
Conditions and timing for reaching target price: This target will likely be realized over the next 9-12 months once Cencora officially cycles past the difficult Q2 FY26 revenue comps and demonstrates two consecutive quarters of aggressive debt reduction.
Stop Loss & Investment Thesis Invalidation Criteria:$245.00 ($240.00–$250.00)
Fundamental damage criteria: An absolute inability to hit the $3.0 billion adjusted free cash flow guidance due to spiraling debt costs, or a structural breakdown in the U.S. segment operating margin below 1.1%.
Action trigger upon catalyst achievement:
1 Achieving $3.0 Billion FCF in FY26 and Aggressive Deleveraging
Description: Proves the debt load from OneOncology is manageable and clears the runway for the $2B buyback execution. 👉 Increased Holdings (Buy)
2 MWI Animal Health Divestiture Finalization
Description: The injection of $1.25 billion in cash solidifies the balance sheet instantly. 👉 Maintain Holdings (Wait)
3 Unforeseen PBM Regulatory Crackdown on Distributor Spreads
Description: Legislative damage to the core U.S. Healthcare Solutions profitability engine. 👉 Reduction in Holdings (Sell)
Action triggers when risk realization:
1 Further Downward Revisions to U.S. Segment Revenue
Description: If manufacturer list price cuts prove structural rather than transitory, top-line growth is permanently impaired. 👉 Reduction in Holdings (Sell)
2 Operating Margin Contracts Below 1.2%
Description: Indicates the high-margin MSO strategy (OneOncology/RCA) is failing to offset the decay in traditional distribution. 👉 Reduction in Holdings (Sell)
3 Credit Rating Downgrade by Fitch or S&P
Description: A downgrade from A- due to delayed deleveraging would spike borrowing costs exponentially. 👉 Reduction in Holdings (Sell)
Customized Strategy Guide by Investment Preference:
Defensive Investors: Wait patiently for a pullback to the $275 Buy Zone to ensure maximum safety margin; rely heavily on the 0.79% yield and aggressive buybacks to limit downside.
Neutral Investors: Initiate a half-position at current levels ($303) and average down if Q3 earnings show lingering revenue softness.
Aggressive Investors: Capitalize on the temporary sentiment dislocation; buy immediately, betting that the OneOncology margin expansion will violently rerate the stock upward by early FY27.
🕵️♂️ Deep Dive Analysis
Q1: Is Cencora’s Operating Margin Vulnerable to Manufacturer Pricing Pressure?
Analysis: The May 2026 earnings shock laid bare a critical, structural vulnerability: Cencora absorbed a staggering $2 billion revenue headwind entirely due to manufacturer list price reductions. As the government (via the Inflation Reduction Act) and PBMs squeeze drugmakers, manufacturers inevitably pass this pain down the supply chain by aggressively cutting wholesale acquisition costs (WAC). Because distributors charge a percentage-based fee on WAC, lower list prices mechanically destroy top-line revenue. However, Cencora’s operating margin actually expanded to 1.46% during this exact same quarter. This occurred because the margin lost from plain-vanilla distribution was more than offset by the massive influx of fee-for-service income generated by newly acquired specialty MSOs like Retina Consultants of America and OneOncology.
Judgment:Neutral — The headline revenue damage is terrifying for algorithmic traders, but the structural reality is that Cencora is successfully rotating its profit pool away from WAC-dependent distribution and toward service-based MSO fees, shielding the actual bottom line.
Q2: Can Cencora’s 17x Forward P/E Be Justified by the OneOncology and GLP-1 Growth Trends?
Analysis: Historically, drug distributors have traded at a depressed 12x to 15x Forward P/E due to their microscopic 1% margins and role as low-value-add middlemen. Cencora’s current ≈17x multiple demands a premium narrative. This narrative relies heavily on GLP-1 agonists (which added $1 billion in volume growth recently) and the $4.6 billion acquisition of OneOncology. GLP-1s, while explosive in volume, are notoriously low-margin and often act as “empty calories” on the income statement. Therefore, the entire burden of justifying the 17x multiple falls on OneOncology. If OneOncology and the broader specialty MSO network can organically grow their high-margin administrative and clinical trial fees by 15%+ annually, the 17x multiple is easily defended.
Judgment:Fairly Valued — The 17x multiple perfectly prices in the successful integration of OneOncology, leaving very little room for error if specialty drug utilization stalls or debt servicing throttles EPS.
Q3: Will Cencora’s $12.4 Billion Debt Load Strangle Free Cash Flow in a High-Rate Environment?
Analysis: Cencora aggressively levered up, tapping $5.5 billion in credit facilities to close OneOncology, pushing total debt to $12.39 billion and driving EBITDA leverage to 2.5x. Consequently, net interest expense skyrocketed to an annualized run rate approaching $485 million. In an era of elevated interest rates, carrying floating-rate term loans is punishing. However, context is paramount. Cencora is an absolute cash-printing juggernaut, firmly guiding for $3.0 billion in adjusted free cash flow for FY26. Furthermore, the $1.25 billion cash injection from the MWI Animal Health divestiture provides an immediate liquidity shock absorber.
Judgment:Positive — While the optics of the debt spike are poor, Cencora generates enough free cash flow to easily digest the interest payments while aggressively deleveraging over the next 24 months to defend its A- credit rating.
Q4: Does the Divestiture of MWI Animal Health Signal a Weakness in Core Diversification?
Analysis: In February 2026, Cencora agreed to merge MWI Animal Health with Covetrus in a $3.5 billion deal, walking away with $1.25 billion in cash and a 34% minority stake. Historically, animal health was prized by distributors for its lack of government regulation and higher margins. Divesting it might appear as a loss of a reliable cash cow. However, it is actually a masterclass in capital allocation. Cencora recognized that the highly fragmented human oncology and retina markets offer vastly superior, compounding returns. By cashing out of the mature animal health space, they freed up billions to dominate the immensely profitable human specialty MSO space (OneOncology, EyeSouth, RCA).
Judgment:Positive — The divestiture is not a retreat; it is a calculated, strategic funneling of resources into the highest-yielding sectors of human medicine.
Q5: How Severely Will Biosimilar Conversions Impact Cencora’s Specialty Revenues?
Analysis: During the Q1 and Q2 2026 earnings calls, executive management cited faster-than-expected brand-to-biosimilar conversions at large mail-order pharmacy clients as a tangible headwind to revenue. Biosimilars are significantly cheaper than their branded biologic counterparts. When a patient switches, the absolute dollar value of the drug flowing through Cencora’s network drops, dragging down reported revenue. However, distributors frequently negotiate higher percentage margins on biosimilars compared to branded drugs. CEO Bob Mauch explicitly noted that in physician-administered channels (Part B), biosimilar conversions are actually neutral or net-positive for operating profit.
Judgment:Neutral — Biosimilar adoption destroys top-line revenue vanity metrics but structurally protects or enhances bottom-line operating profit dollars.
Q6: Can McKesson’s Outperformance Threaten Cencora’s U.S. Market Share?
Analysis: McKesson (MCK) currently boasts a significantly larger market capitalization ($94.36 billion vs Cencora’s $59.04 billion) and generates roughly $403 billion in TTM revenue compared to Cencora’s $328 billion. McKesson has also exhibited more consistent recent earnings beats. However, the U.S. pharmaceutical distribution market is a settled oligopoly. Market share shifts are glacial and usually tied to decade-long contracts with mega-pharmacies (e.g., Cencora’s ironclad relationship with Walgreens). Instead of fighting a bloody war over generic distribution volumes, Cencora has sidestepped McKesson by aggressively rolling up independent specialty physician practices (MSOs), an arena where Cencora is arguably moving faster and more aggressively.
Judgment:Positive — Cencora is not losing a war to McKesson; it is simply playing a different game, prioritizing MSO margin expansion over raw distribution volume.
Q7: Are the Aggressive Insider Purchases by Chairman Mark Durcan a Reliable Bottom Indicator?
Analysis: In late May and June 2026, Independent Chairman Mark Durcan executed multiple open-market purchases, acquiring 8,000 shares for over $2.1 million at prices ranging from $266 to $274. This occurred precisely after the stock collapsed 17% following the Q2 revenue miss. When an Independent Chairman—someone with total visibility into the OneOncology integration and real-time cash flow metrics—drops over $2 million of personal capital into the stock at a specific technical level, it signals extreme conviction that the broader market severely overreacted to the top-line guidance cut.
Judgment:Positive — This is a textbook, high-conviction insider cluster buy that establishes a highly credible fundamental floor for the stock in the $260-$275 range.
Q8: Will the New $2.0 Billion Share Repurchase Program Function as a Protective Put?
Analysis: Cencora paused buybacks in early 2026 to help finance the OneOncology acquisition. The market heavily discounted the stock in May. In brilliant tactical fashion, the Board immediately authorized a new $2.0 billion share repurchase program on May 20, 2026. At a $59 billion market cap, a $2 billion authorization represents the retirement of roughly 3.3% of the outstanding float. More importantly, it provides a massive liquidity bid beneath the stock. If the price drifts lower due to macro weakness, management can step in and mechanically manufacture EPS growth by retiring cheap shares, fully insulating the bottom line.
Judgment:Positive — The swift authorization proves management’s agility and provides a lethal weapon to punish short sellers and stabilize the equity.
Q9: Does the Appointment of Eva Boratto as CFO Signal a Strategic Shift?
Analysis: On June 29, 2026, Eva Boratto took over as CFO. Boratto is a heavy hitter, bringing over a decade of experience from CVS Health, where she served as CFO of the entire enterprise and specifically of Caremark, CVS’s massive Pharmacy Benefit Manager (PBM). Cencora’s greatest current threats are PBM reimbursement pressures and navigating complex drug pricing legislation. Hiring a former PBM executive as CFO is a masterstroke. Boratto inherently understands the exact mechanisms PBMs use to squeeze distributors and can architect financial defenses against them.
Judgment:Positive — Boratto’s deep inside knowledge of PBM economics perfectly equips Cencora to defend its margins in a hostile regulatory pricing environment.
Q10: Is Cencora’s International Healthcare Solutions Segment a Hidden Growth Engine?
Analysis: Often overshadowed by the massive U.S. segment, Cencora’s International Healthcare Solutions delivered $7.6 billion in Q2 2026 revenue (up 13% YoY) and generated $176 million in operating income (up 14% YoY). Anchored by Alliance Healthcare in Europe and the global logistics powerhouse World Courier, this segment provides a crucial hedge against U.S.-specific regulatory pricing shocks. World Courier, in particular, dominates the transport of highly sensitive, temperature-controlled clinical trial drugs globally—a niche with massive barriers to entry and exceptional margins.
Judgment:Positive — The international segment is quietly delivering double-digit operating income growth, acting as a highly reliable, high-margin counterweight to the turbulent U.S. distribution landscape.